Pharmacokinetic characterization 14C-vascular endothelial growth factor controlled release microspheres using a rat model

被引:57
作者
Kim, TK [1 ]
Burgess, DJ [1 ]
机构
[1] Univ Connecticut, Sch Pharm, Storrs, CT 06269 USA
关键词
D O I
10.1211/002235702760089009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objectives of this study were to characterize the pharmacokinetics of vascular endothelial growth factor (VEGF) in poly(lactic-co-glycolic) acid (PLGA) microspheres using a rat model, and to develop a pharmacokinetic model for this controlled release formulation. C-14-VEGF was encapsulated using a solid-in-oil-in-water emulsification method. The microspheres were administered subcutaneously to rats and the pharmacokinetic parameters were compared with those of protein solutions. Intravenous administration of protein solutions resulted in short half-lives and subcutaneous administration resulted in rapid clearance from the subcutaneous tissue, with high plasma concentrations as expressed by rapid absorption and elimination. The subcutaneous administration of the VEGF microspheres produced low plasma concentrations and high subcutaneous concentrations over a period of 7 weeks. The area under the curve (AUC), the time required to achieve the maximum concentration (t(max)), the maximum concentration (C-max) in blood samples and the elimination rate constant (k(el)) values at the subcutaneous tissue site were selected to compare the pharmacokinetic characterization of VEGF microspheres with that of protein solutions. The in-vivo release profiles of the proteins were slower than the in-vitro release profiles and they followed the same trend as the in-vitro and in-vivo PLGA degradation rates. The PLGA microsphere degradation was the determinant step for VEGF release from the microspheres and its absorption at the subcutaneous site. Microspheres appear to be an attractive system for the localized rate-controlled delivery of VEGF. C-14-Methylation via reductive alkylation of VEGF did not affect its mitogenic activity, however approximately 25% activity was lost following release from PLGA microspheres. This loss of activity may be due to degradation in an acidic environment as a result of PLGA degradation.
引用
收藏
页码:897 / 905
页数:9
相关论文
共 22 条
[1]   Structure-property model for membrane partitioning of oligopeptides [J].
Alifrangis, LH ;
Christensen, IT ;
Berglund, A ;
Sandberg, M ;
Hovgaard, L ;
Frokjaer, S .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (01) :103-113
[2]   POTENTIAL USE OF ALBUMIN MICROSPHERES AS A DRUG DELIVERY SYSTEM .2. INVIVO DEPOSITION AND RELEASE OF STEROIDS [J].
BURGESS, DJ ;
DAVIS, SS .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1988, 46 (1-2) :69-76
[3]  
Christinger HW, 1996, PROTEINS, V26, P353, DOI 10.1002/(SICI)1097-0134(199611)26:3<353::AID-PROT9>3.0.CO
[4]  
2-E
[5]   The stability of recombinant human growth hormone in poly(lactic-co-glycolic acid) (PLGA) microspheres [J].
Cleland, JL ;
Mac, A ;
Boyd, B ;
Yang, J ;
Duenas, ET ;
Yeung, D ;
Brooks, D ;
Hsu, C ;
Chu, H ;
Mukku, V ;
Jones, AJS .
PHARMACEUTICAL RESEARCH, 1997, 14 (04) :420-425
[6]   Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues [J].
Crotts, G ;
Park, TG .
JOURNAL OF MICROENCAPSULATION, 1998, 15 (06) :699-713
[7]   PITUITARY FOLLICULAR CELLS SECRETE A NOVEL HEPARIN-BINDING GROWTH-FACTOR SPECIFIC FOR VASCULAR ENDOTHELIAL-CELLS [J].
FERRARA, N ;
HENZEL, WJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 161 (02) :851-858
[8]  
FOX BW, 1976, LAB TECHNIQUES BIOCH, P222
[9]  
HALPERIN JA, 1995, US PHARMACOPEIA NATL
[10]   The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency [J].
Keyt, BA ;
Berleau, LT ;
Nguyen, HV ;
Chen, H ;
Heinsohn, H ;
Vandlen, R ;
Ferrara, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (13) :7788-7795